Side chain modifications of (indol-3-yl)glyoxamides as antitumor agents

Abstract

New series of analogues of N-(pyridin-4-yl)-2-[1-(4-chlorobenzyl)-indol- 3-yl]glyoxamide D-24851 were synthesized, characterized and tested for their in vitro anticancer properties. In the first series, an amino acid spacer was introduced in the glyoxamide chain of D-24851. In the second series, the glyoxamide chain was moved to positions 4 and 5 of indole skeleton. These new compounds were tested on four cancer cell lines (KB, SK-OV-3, NCI-H460 and SF-268), with promising activity for the glycine derivative.